Quanterix completes Akoya acquisition for ~7.8M shares + $20M cash; TAM expands to $5B

Quanterix Corp

Quanterix issued ~7.8M shares and paid ~$20M cash to buy Akoya, creating integrated blood & tissue biomarker platform.
Combined addressable market grows from $1B to $5B; company expects accelerated path to profitability by 2026.
CEO Masoud Toloue and CFO Vandana Sriram continue; new board members Scott Mendel and Myla Lai-Goldman appointed.
Prior directors Martin Madaus and Sarah Hlavinka resigned effective at closing; cash balance ~$163M post-transaction.
Historical financials of Akoya and pro forma financials to be filed within 71 days via 8-K/A.

item 2.01item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.